Investors Encouraged to Participate in REGENXBIO Securities Fraud Litigation Investors of REGENXBIO, Inc. can join a significant securities fraud lawsuit. The deadline for acting is April 14, 2026, for potential lead plaintiffs.

Investors Encouraged to Participate in REGENXBIO Securities Fraud Litigation #United_States #New_York #Rosen_Law_Firm #REGENXBIO #RGNX

Class Action Lawsuit Opportunity for REGENXBIO Investors: Schall Law Firm Leads the Charge Investors in REGENXBIO Inc. have a chance to join a class action lawsuit led by the Schall Law Firm over significant misleading statements about RGX-111.

Class Action Lawsuit Opportunity for REGENXBIO Investors: Schall Law Firm Leads the Charge #USA #Los_Angeles #Schall_Law_Firm #REGENXBIO #RGX-111

Recent Class Action Lawsuit Filed Against REGENXBIO Inc. for Securities Violations REGENXBIO Inc. faces a class action lawsuit over securities law violations, raising concerns for shareholders and investors. Details inside.

Recent Class Action Lawsuit Filed Against REGENXBIO Inc. for Securities Violations #USA #Class_Action #Securities_Law #Eastchester #REGENXBIO

Faruqi & Faruqi Alerts Investors About RGNX Class Action Lawsuit Deadline Faruqi & Faruqi, LLP is reminding investors in REGENXBIO (RGNX) about the approaching deadline for filing claims related to the company's class action lawsuit.

Faruqi & Faruqi Alerts Investors About RGNX Class Action Lawsuit Deadline #USA #New_York #Faruqi_&_Faruqi #REGENXBIO #RGNX

Opportunities for RGNX Investors to Join REGENXBIO Securities Fraud Litigation REGENXBIO investors can seize an opportunity to lead a securities fraud lawsuit. Important deadline approaching for class action participation.

Opportunities for RGNX Investors to Join REGENXBIO Securities Fraud Litigation #USA #New_York #Rosen_Law_Firm #REGENXBIO #RGNX

Robbins LLP Urges REGENXBIO Shareholders to Know Their Rights Amid Class Action Robbins LLP has announced a class action for REGENXBIO investors, encouraging them to understand their rights and potential claims regarding recent allegations.

Robbins LLP Urges REGENXBIO Shareholders to Know Their Rights Amid Class Action #United_States #San_Diego #Robbins_LLP #REGENXBIO #RGNX

Understanding the Recent Class Action Lawsuit Against REGENXBIO Inc. and Its Implications A recent class action lawsuit has been filed against REGENXBIO Inc. concerning securities fraud. Investors should be aware of the implications and deadlines.

Understanding the Recent Class Action Lawsuit Against REGENXBIO Inc. and Its Implications #USA #New_York #Class_Action #Securities_Fraud #REGENXBIO

Investors of REGENXBIO Have the Chance to Lead Securities Fraud Case Following Misleading Statements REGENXBIO, Inc. regarding potential securities fraud offers investors a chance to recover losses due to misleading information during the Class Period.

Investors of REGENXBIO Have the Chance to Lead Securities Fraud Case Following Misleading Statements #United_States #New_York #Securities_Fraud #Rosen_Law_Firm #REGENXBIO

Investors Can Join Class Action Against REGENXBIO Inc. for Securities Fraud Recent developments indicate that investors may take action regarding REGENXBIO Inc.'s alleged securities fraud through a class action lawsuit led by Schall Law Firm.

Investors Can Join Class Action Against REGENXBIO Inc. for Securities Fraud #United_States #Los_Angeles #Schall_Law_Firm #Securities_Fraud #REGENXBIO

Regenxbio Faces Securities Class Action Lawsuit Over Misleading Statements and Investor Losses Regenxbio Inc. is under fire for securities law violations, prompting a class action lawsuit targeting misleading statements about its drug RGX-111 impact on investors.

Regenxbio Faces Securities Class Action Lawsuit Over Misleading Statements and Investor Losses #USA #DJS_Law_Group #Eastchester #REGENXBIO #RGX-111

Investors Alert: Deadline Approaching for REGENXBIO Class Action Lawsuit on April 14, 2026 Faruqi & Faruqi LLP advises investors in REGENXBIO of an approaching deadline for a securities class action. April 14, 2026, marks the date to act.

Investors Alert: Deadline Approaching for REGENXBIO Class Action Lawsuit on April 14, 2026 #USA #New_York #Securities_Class_Action #Faruqi_&_Faruqi #REGENXBIO

Pomerantz Law Firm Alerts Investors of Class Action Against REGENXBIO Inc. - Important Deadlines Approaching Pomerantz Law Firm notifies investors of possible securities fraud linked to REGENXBIO Inc. Class action lawsuit filed, deadlines imminent.

Pomerantz Law Firm Alerts Investors of Class Action Against REGENXBIO Inc. - Important Deadlines Approaching #USA #New_York #Pomerantz #REGENXBIO #RGNX

Important Update for REGENXBIO Inc. Shareholders: Class Action Lawsuit Details Attention REGENXBIO Inc. shareholders! A class action lawsuit has been filed. Key dates and actions for shareholders included.

Important Update for REGENXBIO Inc. Shareholders: Class Action Lawsuit Details #United_States #New_York #Gross_Law_Firm #REGENXBIO #RGX-111

Important Securities Class Action Deadline for REGENXBIO Investors Approaches in April 2026 Investors in REGENXBIO should be aware of the impending deadline on April 14, 2026, for a securities class action. Legal claims are being investigated.

Important Securities Class Action Deadline for REGENXBIO Investors Approaches in April 2026 #United_States #New_York #Class_Action #Faruqi_&_Faruqi #REGENXBIO

Important Opportunity for REGENXBIO Investors in Securities Fraud Case Investors of REGENXBIO, Inc. may have the chance to lead a securities fraud class action lawsuit. The deadline is set for April 14, 2026.

Important Opportunity for REGENXBIO Investors in Securities Fraud Case #USA #New_York #Securities_Fraud #Rosen_Law_Firm #REGENXBIO

Investors Advised on Class Action Lawsuit Against REGENXBIO Inc. Following FDA Announcement Pomerantz LLP alerts REGENXBIO Inc. investors about a class action lawsuit triggered by stock price drop due to FDA news. Join before deadlines.

Investors Advised on Class Action Lawsuit Against REGENXBIO Inc. Following FDA Announcement #USA #New_York #Class_Action #Securities_Fraud #REGENXBIO

Stephen Pakola Faces Allegations Over Safety Claims in REGENXBIO Lawsuit Stephen Pakola, M.D., of REGENXBIO is facing securities lawsuits over safety claims related to RGX-111, leading to significant investor losses.

Stephen Pakola Faces Allegations Over Safety Claims in REGENXBIO Lawsuit #United_States #New_York #REGENXBIO #RGX-111 #Stephen_Pakola

Important Notice for REGENXBIO Investors on Securities Class Action Deadline by Faruqi & Faruqi Faruqi & Faruqi, LLP is reminding investors of REGENXBIO about a critical securities class action deadline on April 14, 2026. Investors should act now.

Important Notice for REGENXBIO Investors on Securities Class Action Deadline by Faruqi & Faruqi #USA #New_York #Faruqi_&_Faruqi #REGENXBIO #RGNX

RGNX Shareholders May Pursue Class Action Against REGENXBIO Inc. for Misleading Information Shareholders of REGENXBIO Inc. (NASDAQ: RGNX) are encouraged to seek leadership positions in a class action lawsuit due to alleged misleading communications by the company.

RGNX Shareholders May Pursue Class Action Against REGENXBIO Inc. for Misleading Information #USA #New_York #Class_Action #REGENXBIO #RGNX

Investors Can Step Forward in REGENXBIO Securities Fraud Case The Rosen Law Firm invites investors of REGENXBIO, Inc. to participate in a securities fraud lawsuit regarding RGX-111. The deadline is April 14, 2026.

Investors Can Step Forward in REGENXBIO Securities Fraud Case #USA #New_York #Securities_Fraud #REGENXBIO #RGNX

REGENXBIO se complace compartir las actualizaciones sobre el ensayo de Fase I/II AFFINITY DUCHENNE® de RGX-202*, la terapia génica en investigación de REGENXBIO para la distrofia muscular de Duchenne.

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO #AFFINITYDUCHENNE

Regenxbio, Solid report data with Duchenne gene therapies Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.

This week saw both #Regenxbio and #SolidBio report new #data with their #genetherapy candidates for #Duchenne muscular dystrophy (DMD), vying to join Sarepta's Elevidys on the market.

Pomerantz Law Firm Warns Investors About Class Action Lawsuit Against REGENXBIO Inc. Pomerantz Law Firm has filed a class action against REGENXBIO Inc. following allegations of securities fraud. Investors have upcoming deadlines to participate.

Pomerantz Law Firm Warns Investors About Class Action Lawsuit Against REGENXBIO Inc. #USA #New_York #Pomerantz #REGENXBIO #RGNX

REGENXBIO's Dr. Stephen Pakola Faces Securities Class Action for Misleading Investors Over RGX-111 Safety Dr. Stephen Pakola of REGENXBIO faces serious allegations in a securities class action claiming he misled investors about RGX-111's safety, resulting in steep financial losses.

REGENXBIO's Dr. Stephen Pakola Faces Securities Class Action for Misleading Investors Over RGX-111 Safety #USA #New_York #REGENXBIO #RGX-111 #Stephen_Pakola

REGENXBIO Unveils Promising Interim Data from Phase I/II Trial for Duchenne's Disease Treatment REGENXBIO announces encouraging interim results from its RGX-202 trial, showing promise for Duchenne muscular dystrophy treatment with improved functionality and stability.

REGENXBIO Unveils Promising Interim Data from Phase I/II Trial for Duchenne's Disease Treatment #United_States #Rockville #Duchenne #REGENXBIO #RGX-202

Important Reminder for REGENXBIO Investors on Class Action Deadline Approaching Soon Faruqi & Faruqi, LLP informs REGENXBIO investors of an impending deadline for joining a federal securities class action set for April 14, 2026.

Important Reminder for REGENXBIO Investors on Class Action Deadline Approaching Soon #United_States #New_York #Securities_Class_Action #Faruqi_&_Faruqi #REGENXBIO

Investors of REGENXBIO Inc. Urged to Join Class Action Lawsuit for Recovering Losses Investors who faced financial losses with REGENXBIO Inc. can join a class action lawsuit led by Levi & Korsinsky to recover damages related to alleged securities fraud.

Investors of REGENXBIO Inc. Urged to Join Class Action Lawsuit for Recovering Losses #United_States #New_York #Levi_&_Korsinsky #REGENXBIO #RGNX

Class Action Alert for REGENXBIO Investors: Legal Steps and Timeline for Shareholders The Gross Law Firm invites REGENXBIO Inc. investors to join a class action legal case following substantial losses stemming from misleading company statements.

Class Action Alert for REGENXBIO Investors: Legal Steps and Timeline for Shareholders #USA #New_York #Gross_Law_Firm #REGENXBIO #RGX-111

Opportunity for RGNX Investors to Lead REGENXBIO Class Action Lawsuit REGENXBIO, Inc. investors can join a class action lawsuit for compensation regarding securities fraud. Important deadlines approaching.

Opportunity for RGNX Investors to Lead REGENXBIO Class Action Lawsuit #United_States #New_York #Securities #REGENXBIO #RGNX

Important Deadline Approaches for REGENXBIO Investors in Class Action Lawsuit Investors in REGENXBIO are reminded of an impending deadline to join a federal class action lawsuit before April 14, 2026, led by Faruqi & Faruqi, LLP.

Important Deadline Approaches for REGENXBIO Investors in Class Action Lawsuit #USA #New_York #Class_Action #Faruqi_&_Faruqi #REGENXBIO